Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Carotuximab |
| Trade Name | |
| Synonyms | TRC105|TRC-105|TRC 105 |
| Drug Descriptions |
Carotuximab (TRC105) is a monoclonal antibody that binds to endoglin (CD105), a TGF beta-1 accessory receptor highly expressed on tumor vessel endothelial cells, blocking signaling essential for angiogenesis and potentially decreasing proliferation of tumor cells (PMID: 28465443). |
| DrugClasses | TGFBR inhibitor (pan) 2 |
| CAS Registry Number | 1268714-50-6 |
| NCIT ID | C74010 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Abiraterone + Carotuximab | Abiraterone Carotuximab | 0 | 1 |
| Apalutamide + Carotuximab | Apalutamide Carotuximab | 0 | 1 |
| Axitinib + Carotuximab | Axitinib Carotuximab | 0 | 1 |
| Bevacizumab + Carotuximab | Bevacizumab Carotuximab | 0 | 4 |
| Capecitabine + Carotuximab | Capecitabine Carotuximab | 0 | 1 |
| Carotuximab | Carotuximab | 0 | 3 |
| Carotuximab + Enzalutamide | Carotuximab Enzalutamide | 0 | 1 |
| Carotuximab + Everolimus + Letrozole | Carotuximab Everolimus Letrozole | 0 | 1 |
| Carotuximab + Nivolumab | Carotuximab Nivolumab | 0 | 1 |
| Carotuximab + Osimertinib | Carotuximab Osimertinib | 0 | 1 |
| Carotuximab + Pazopanib | Carotuximab Pazopanib | 0 | 3 |
| Carotuximab + Sorafenib | Carotuximab Sorafenib | 0 | 2 |